Merck & Co., Inc., Johnson & Johnson’s New Hepatitis C Treatment Fetches $31,000 in France

Bloomberg -- New hepatitis C drugs from Merck & Co. and Johnson & Johnson (JNJ) are being sold in France for 22,000 euros ($31,271) and more, a precedent some doctors say may limit access after the medicines are approved throughout Europe.